Off‐label use of intravenous antimicrobials for inhalation in patients with cystic fibrosis-Reference-Cited by-同舟云学术

Off‐label use of intravenous antimicrobials for inhalation in patients with cystic fibrosis

Published:2019-11 Issue:S3 Volume:54 Page:
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatr Pulmonol

Author:

McKinzie Cameron J.¹^ORCID,Chen Lori²,Ehlert Kim³,Grisso Alison G.⁴,Linafelter Alaina⁵,Lubsch Lisa⁶⁷,O'Brien Catherine E.⁸,Pan Alice C.⁹,Wright Brittany A.¹⁰^ORCID,Elson E. Claire⁵

Affiliation:

1. Department of PharmacyUniversity of North Carolina Medical CenterChapel Hill North Carolina

2. Department of PharmacyThe Hospital for Sick ChildrenToronto Ontario Canada

3. Department of PharmacyFairview Health ServicesMinneapolis Minnesota

4. Department of PharmacyMonroe Carell Jr Children's Hospital at VanderbiltNashville Tennessee

5. Department of PharmacyChildren's Mercy Kansas CityKansas City Missouri

6. Department of Pharmacy, PracticeSouthern Illinois University Edwardsville School of PharmacyEdwardsville Missouri

7. Department of PharmacyCardinal Glennon Children's HospitalSt Louis Missouri

8. Department of Pharmacy PracticeUniversity of Arkansas for Medical Sciences College of PharmacyLittle Rock Arkansas

9. Department of PharmacyThe Johns Hopkins HospitalBaltimore Maryland

10. Department of Pharmaceutical CareUniversity of Iowa Health CareIowa City Iowa

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.24511

Reference95 articles.

1. 2018 Novartis Pharmaceuticals East Hanover NJ Tobi (tobramycin) [package insert]

2. Bethkis [package insert].Woodstock IL:Chiesi USA Inc;August 2018.

3. 2014 Novartis Pharmaceuticals Corporation East Hanover NJ Tobi Podhaler [package insert]

4. Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis

5. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Dry Hyaluronic Acid–Vancomycin Complex Powder for Inhalation, Useful in Pulmonary Infections Associated with Cystic Fibrosis;Pharmaceutics;2024-03-22

2. The Risk of Developing of Malnutrition and the Principles of Correction of Nutritional Status Disorders in Children with Cystic Fibrosis;Pediatric pharmacology;2023-11-17

3. Role of inhaled antibiotics in the era of highly effective CFTR modulators;European Respiratory Review;2023-01-11

4. Pseudomonas aeruginosa is oxygen-deprived during infection in cystic fibrosis lungs, reducing the effectiveness of antibiotics;FEMS Microbiology Letters;2023

5. El papel de los antibióticos inhalados en la era de los moduladores de CFTR de alta eficacia;Kompass Neumología;2023